LOGIN  |  REGISTER
Cue Biopharma

Penumbra to Present at Upcoming Investor Conferences

April 25, 2023 | Last Trade: US$257.81 5.58 2.21

ALAMEDA, Calif., April 25, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following investor conferences on the dates and times listed below:

Event:

Bank of America Securities 2023 Health Care Conference

Date:

Tuesday, May 9, 2023

Time:

1:40pm ET / 10:40am PT

  

Event:

2023 RBC Capital Markets Global Healthcare Conference

Date:

Tuesday, May 16, 2023

Time:

11:30am ET / 8:30am PT

Webcasts of the presentations will be available by visiting the investors' section of the company's website at www.penumbrainc.com.  The webcasts will be available on the company's website for at least two weeks following the event.

About Penumbra

Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra supports healthcare providers, hospitals and clinics in more than 100 countries. For more information, visit www.penumbrainc.com and connect on Twitter and LinkedIn.

Investor Relations

Penumbra, Inc.
510-995-2461
This email address is being protected from spambots. You need JavaScript enabled to view it.

Assertio

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page